Observational studyFrontiers in immunology2025
Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study.
Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Site-level cutaneous phenotyping framework for anti-MDA5-positive dermatomyositis: exploratory associations with systemic immune reference markers.Arthritis research & therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5+DM) is associated with poor prognosis and high mortality, presenting significant challenges for treating this intractable disease. This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. Methods: In this retrospective observational study, MDA5+DM patients from the First Affiliated Hospital of Zhengzhou University between August 2019 and June 2024 were included. Patients were categorized into three groups according to the different immunosuppressive regimens. One-year mortality and the potential risk factors for death was analyzed using the Kaplan-Meier survival analysis and Cox proportional hazards regression, respectively. Results: A total of 152 patients were divided into CNI group(n=49, 32.2%), CNI+TOF group(n=52, 34.2%), and CNI+CTX group(n=51, 33.6%). The 1-year survival rate was significantly lower in the CNI group compared to in the combination therapy groups (logrank P = 0.032). However, the CNI+CTX group showed a higher overall infection rate compared to CNI and CNI+TOF group (51.0% vs 28.6% vs 32.7%, p=0.048). Multivariate analysis identified combination therapy and higher CD8+ T cells act as protective factors, whereas co-infection is a major predictor of mortality. Conclusions: In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.